|
| Press Releases |
|
 |
|
| Wednesday, May 29, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting |
| Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States. more info >> |
|
| Friday, May 17, 2019 |
|
|
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets |
| Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction. more info >> |
|
| Thursday, May 16, 2019 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting |
| Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. more info >> |
|
| Friday, May 10, 2019 |
|
|
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan |
| Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan. Medac will submit a manufacturing and marketing authorization application for the product after conducting a clinical study in Japan. more info >> |
|
|
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 |
| These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai. more info >> |
|
| Thursday, May 9, 2019 |
|
|
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions |
| Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care. more info >> |
|
|
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform. more info >> |
|
| Wednesday, May 8, 2019 |
|
|
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research |
| Eisai Co., Ltd. and the UK Dementia Research Institute (UK DRI) announced today the launch of a joint post-doctoral programme to support the advancement of novel dementia research. more info >> |
|
| Wednesday, May 1, 2019 |
|
|
Eisai Buys Out Purdue Rights to End Collaboration |
| Eisai group will solely conduct the development and the commercialization of lemborexant globally. more info >> |
|
| Wednesday, April 24, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting |
| Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist lemborexant and its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 2019 Annual American Academy of Neurology (AAN) Meeting to be held from May 4 to 10, 2019 in Philadelphia, Pennsylvania in the United States. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cornerstone Robotics Completes the World's First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery 
Aug 6, 2025 19:21 HKT/SGT
|
|
|
" title="Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
">
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 6, 2025 19:40 JST
|
|
|
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 6, 2025 18:54 JST
|
|
|
International Land Alliance Brings Baja to Buyers with Live Zoom Webinar Experience
Aug 6, 2025 17:32 HKT/SGT
|
|
|
Luxren Capital Rolls Out High-Performance Mobile Trading App for Global Users
Aug 6, 2025 17:00 HKT/SGT
|
|
|
MyFintech Week 2025 Highlights Transformative Forces in Finance
Aug 6, 2025 17:00 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 6, 2025 16:35 HKT/SGT
|
|
|
iFex Capital Launches Major Mobile Trading App Overhaul to Meet Surging Demand
Aug 6, 2025 16:00 HKT/SGT
|
|
|
35th Food Expo opens next week five theme days kick off premium lifestyle journey
Aug 6, 2025 15:05 HKT/SGT
|
|
|
AITO launches EV Road Tour from Chongqing to Jakarta
Aug 6, 2025 14:22 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 6, 2025 13:20 HKT/SGT
|
|
|
University of Cyberjaya Welcomes Education Reforms under RMK13: A Bold Step Toward Future-Ready Talent and Inclusive Innovation
Aug 6, 2025 12:27 HKT/SGT
|
|
|
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 6, 2025 11:00 JST
|
|
|
TruMerit Launches Global Credential for First-Level, General Nurses
Aug 6, 2025 09:00 HKT/SGT
|
|
|
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 5, 2025 22:02 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
